Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

First Phase III Study with Targacept and AstraZeneca’s Adjunctive Antidepressant Misses Primary Endpoint

Renaissance 3 study found that adding TC-5214 to SSRI/SNRI therapy for eight weeks failed to change MADRS score.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

Biopharma Layoffs: Relocate or Not?

Would you relocate to another country for a job?

Suggest a Poll